EGFR-mutated NSCLC on Erlotinib/Tarceva with March CT pending

Patient Info: Anonymized, Male

Biomarkers: EGFR mutation; T790M discussed as a possible later resistance mutation

As of February 2015, he was about 1.5 months into Erlotinib/Tarceva for EGFR-mutated NSCLC and was waiting for a March CT to know whether the tumor was controlled.

EGFR-mutated lung cancer diary: PET-scan anxiety during treatment break

Patient Info: Anonymized, Male

Biomarkers: EGFR mutation

As of December 2014, the patient had been off treatment for 6 months with limited symptoms and was awaiting a PET scan to determine whether treatment should restart.

EGFR exon 19 lung adenocarcinoma with bone and brain metastases: brain lesions resolved on gefitinib

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: lumbar spine, pelvic bone, brain (left occipital lobe,…

As of March 2014, asymptomatic brain metastases had regressed after 1 month of gefitinib and were no longer discernible after another 3 months, while lumbar vertebral disease was treated with radiotherapy.

PubMed CentralRead more →

Stage IIIA NSCLC with superior vena cava tumor thrombus: complete response to radiation and erlotinib

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: EGFR protein expression positive; EGFR gene mutation not tested because tumor sample was inadequate

Radiation plus erlotinib led to complete response of the primary lung tumor at 6 months, disappearance of the SVC thrombosis at 9 months, and no progression during 45 months of close follow-up on maintenance erlotinib.

PubMed CentralRead more →

EGFR L858R-mutant Stage IV lung adenocarcinoma managed after gefitinib-induced lung injury

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: EGFR L858R mutation

Metastatic Site: liver, bone, hilar lymph nodes, mediastinal lymph…

Gefitinib produced early tumor shrinkage but was stopped for interstitial lung disease; subsequent carboplatin, pemetrexed, and bevacizumab produced a good response, while variceal bleeding was controlled with endoscopic treatment.

PubMed CentralRead more →

Sigmoid colon cancer with later inguinal lymph-node metastasis: surgery, FOLFOX, FOLFIRI, and cetuximab

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: CEA was elevated at diagnosis and recurrence. Metastatic lymph node was CK20 positive/CK7 negative; EGFR mutation status not reported.

Metastatic Site: left inguinal lymph node

Apparently disease-free 8 months after surgical removal of the left inguinal lymph-node metastasis followed by FOLFIRI plus cetuximab.

PubMed CentralRead more →